ReviewExpert review of vaccines2010
New flow cytometric assays for monitoring cell-mediated cytotoxicity.
Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.Frontiers in immunology · 2020Pooled it
- Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2016Pooled it
- Review of in vitro approaches for assessing the toxicity of chemical stressors across diverse physiological systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- Evaluation of Murine Tissue Architecture and Cellular Spatial Relationships in Murine Tumor Microenvironments Utilizing Multiplex Fluorescent Immunohistochemistry.Methods in molecular biology (Clifton, N.J.) · 2026Article
- JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab.Frontiers in neurology · 2025Article
- Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging.Journal of visualized experiments : JoVE · 2023Article
- Modulating the Effect of β-Sitosterol Conjugated with Magnetic Nanocarriers to Inhibit EGFR and Met Receptor Cross Talk.Pharmaceutics · 2023Article
- Article
- Release Assays and Potency Assays for CAR T-Cell Interventions.Advances in experimental medicine and biology · 2023Article
- Multiplex Fluorescent Immunohistochemistry for Preservation of Tumor Microenvironment Architecture and Spatial Relationship of Cells in Tumor Tissues.Methods in molecular biology (Clifton, N.J.) · 2023Article
- The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Cytotoxic Efficiency of Human CD8Frontiers in immunology · 2022Article
- The Biodegradability andFrontiers in bioengineering and biotechnology · 2022Article
- Overcoming biological barriers to improve solid tumor immunotherapy.Drug delivery and translational research · 2021Review
- A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells.iScience · 2021Article
- Flow Cytometric Analysis of the Cytotoxic T-Cell Recall Response toVeterinary sciences · 2021Article
- A novel thermostable beetle luciferase based cytotoxicity assay.Scientific reports · 2021Article
- Melanoma-associated fibroblasts impair CD8+ T cell function and modify expression of immune checkpoint regulators via increased arginase activity.Cellular and molecular life sciences : CMLS · 2021Article
- Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines.Frontiers in molecular biosciences · 2021Review
- CRISPR/Cas9-Mediated GFP Reporter Knock-in in K562 and Raji Cell Lines for Tracking Immune Cell Killing Assay.Methods in molecular biology (Clifton, N.J.) · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The exact immunologic responses after vaccination that result in effective antitumor immunity have not yet been fully elucidated and the data from ex vivo T-cell assays have not yet defined adequate surrogate markers for clinical efficacy. A more detailed knowledge of the specific immune responses that correlate with positive clinical outcomes should help to develop better or novel strategies to effectively activate the immune system against tumors. Furthermore, clinically relevant material is often limited and, thus, precludes the ability to perform multiple assays. The two main assays currently used to monitor lymphocyte-mediated cytoxicity in cancer patients are the (51)Cr-release assay and IFN-gamma ELISpot assay. The former has a number of disadvantages, including low sensitivity, poor labeling and high spontaneous release of isotope from some tumor target cells. Additional problems with the (51)Cr-release assay include difficulty in obtaining autologous tumor targets, and biohazard and disposal problems for the isotope. The ELISpot assays do not directly measure cytotoxic activity and are, therefore, a surrogate marker of cyotoxic capacity of effector T cells. Furthermore, they do not assess cytotoxicity mediated by the production of the TNF family of death ligands by the cytotoxic cells. Therefore, assays that allow for the simultaneous measurement of several parameters may be more advantageous for clinical monitoring. In this respect, multifactor flow cytometry-based assays are a valid addition to the currently available immunologic monitoring assays. Use of these assays will enable detection and enumeration of tumor-specific cytotoxic T lymphocytes and their specific effector functions and any correlations with clinical responses. Comprehensive, multifactor analysis of effector cell responses after vaccination may help to detect factors that determine the success or failure of a vaccine and its immunological potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.